← Joinn Laboratories(China)Co overview

Joinn Laboratories(China)Co vs Agilent: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Joinn Laboratories(China)Co (603127.CG)

Q3 2026
▲3▼1

Joinn profit surge and CRO sector rally drive gains

  • H1 profit forecast surge on biological asset gains Joinn forecast first-half 2026 net profit of 600–900 million yuan, up 884.9%–1,377.4% year-on-year. The jump is mostly from higher market prices and natural growth of biological assets (lab monkeys), not from lab operations, which grew only slightly. This boosts reported earnings and investor sentiment.

    This is the primary new company-specific catalyst that directly explains the profit surge and initial stock reaction.

  • Rising lab monkey prices lift CRO profits The price of cynomolgus monkeys, a key raw material for CROs, climbed to 178,000 yuan. This directly boosts the value of Joinn's biological assets and its profit forecast, as seen across the sector. Higher animal prices support earnings but also raise costs for drug testing services.

    It explains the underlying driver of Joinn's profit surge and links it to a sector-wide trend.

  • CRO sector rally on strong peer earnings and order recovery On August 7, the A-share CRO sector jumped over 7%, with 15 stocks up more than 10%. Strong results from WuXi AppTec and BioMap, plus rising orders from recovering global pharma R&D demand, lifted the whole group including Joinn. This sector momentum supports Joinn's share price.

    It shows the broader sector force currently pushing Joinn's stock higher, beyond its own earnings.

  • Pharmaceutical sector selloff pressures CRO stocks On July 17, the pharmaceutical sector tumbled, with CRO concept stocks like Joinn falling and peers hitting daily limit down. This shows that despite strong earnings, the sector remains sensitive to broad market risk-off moves, which can drag Joinn's price down in the short term.

    It provides a real counterweight: sector volatility can still pressure Joinn even amid positive earnings news.

July 2026
▲3▼1

Joinn profit surge and CRO sector rally drive gains

  • H1 profit forecast surge on biological asset gains Joinn forecast first-half 2026 net profit of 600–900 million yuan, up 884.9%–1,377.4% year-on-year. The jump is mostly from higher market prices and natural growth of biological assets (lab monkeys), not from lab operations, which grew only slightly. This boosts reported earnings and investor sentiment.

    This is the primary new company-specific catalyst that directly explains the profit surge and initial stock reaction.

  • Rising lab monkey prices lift CRO profits The price of cynomolgus monkeys, a key raw material for CROs, climbed to 178,000 yuan. This directly boosts the value of Joinn's biological assets and its profit forecast, as seen across the sector. Higher animal prices support earnings but also raise costs for drug testing services.

    It explains the underlying driver of Joinn's profit surge and links it to a sector-wide trend.

  • CRO sector rally on strong peer earnings and order recovery On August 7, the A-share CRO sector jumped over 7%, with 15 stocks up more than 10%. Strong results from WuXi AppTec and BioMap, plus rising orders from recovering global pharma R&D demand, lifted the whole group including Joinn. This sector momentum supports Joinn's share price.

    It shows the broader sector force currently pushing Joinn's stock higher, beyond its own earnings.

  • Pharmaceutical sector selloff pressures CRO stocks On July 17, the pharmaceutical sector tumbled, with CRO concept stocks like Joinn falling and peers hitting daily limit down. This shows that despite strong earnings, the sector remains sensitive to broad market risk-off moves, which can drag Joinn's price down in the short term.

    It provides a real counterweight: sector volatility can still pressure Joinn even amid positive earnings news.

Latest
▲3▼1

Joinn profit surge and CRO sector rally drive gains

  • H1 profit forecast surge on biological asset gains Joinn forecast first-half 2026 net profit of 600–900 million yuan, up 884.9%–1,377.4% year-on-year. The jump is mostly from higher market prices and natural growth of biological assets (lab monkeys), not from lab operations, which grew only slightly. This boosts reported earnings and investor sentiment.

    This is the primary new company-specific catalyst that directly explains the profit surge and initial stock reaction.

  • Rising lab monkey prices lift CRO profits The price of cynomolgus monkeys, a key raw material for CROs, climbed to 178,000 yuan. This directly boosts the value of Joinn's biological assets and its profit forecast, as seen across the sector. Higher animal prices support earnings but also raise costs for drug testing services.

    It explains the underlying driver of Joinn's profit surge and links it to a sector-wide trend.

  • CRO sector rally on strong peer earnings and order recovery On August 7, the A-share CRO sector jumped over 7%, with 15 stocks up more than 10%. Strong results from WuXi AppTec and BioMap, plus rising orders from recovering global pharma R&D demand, lifted the whole group including Joinn. This sector momentum supports Joinn's share price.

    It shows the broader sector force currently pushing Joinn's stock higher, beyond its own earnings.

  • Pharmaceutical sector selloff pressures CRO stocks On July 17, the pharmaceutical sector tumbled, with CRO concept stocks like Joinn falling and peers hitting daily limit down. This shows that despite strong earnings, the sector remains sensitive to broad market risk-off moves, which can drag Joinn's price down in the short term.

    It provides a real counterweight: sector volatility can still pressure Joinn even amid positive earnings news.

Agilent Technologies Inc (A)

Q3 2026
▲3▼1

Agilent lifts guidance as China rebounds and diagnostics expand

  • AI cell analysis software and strong Q3 outlook Agilent launched AI-powered cell analysis software and guided Q3 revenue to $1.83–1.85 billion, above consensus. This shows its products are in demand and management is confident, which supports a higher stock price.

    New product and guidance signal future growth, a key driver for the stock.

  • FDA and EU approvals for cancer companion diagnostics Agilent won FDA and EU approvals for its PD-L1 tests in esophageal, gastric, and ovarian cancers. These tie its tests to blockbuster drugs, expanding its diagnostics business and adding steady revenue, which lifts the stock.

    Regulatory wins open new markets and deepen partnerships, directly boosting future sales.

  • Raised FY2026 guidance on China rebound and pharma growth Agilent raised full-year EPS guidance to $6.18–$6.21 after Q3 revenue rose 7.3% and China grew 9%. Strong pharma and advanced therapeutics demand, plus a $1 billion reshoring opportunity, point to faster growth ahead.

    Guidance raise and China recovery are the biggest new fundamental drivers for the stock.

  • Competition and sector sensitivity remain risks Danaher's Leica is expanding in pathology, and the life sciences tools sector is sensitive to growth outlook cuts. These pressures could cap Agilent's gains if investors worry about market share or a broader slowdown.

    Provides a fair counterweight to the positive news, showing what could hold the stock back.

August 2026
▲3▼1

Agilent lifts guidance as China rebounds and diagnostics expand

  • AI cell analysis software and strong Q3 outlook Agilent launched AI-powered cell analysis software and guided Q3 revenue to $1.83–1.85 billion, above consensus. This shows its products are in demand and management is confident, which supports a higher stock price.

    New product and guidance signal future growth, a key driver for the stock.

  • FDA and EU approvals for cancer companion diagnostics Agilent won FDA and EU approvals for its PD-L1 tests in esophageal, gastric, and ovarian cancers. These tie its tests to blockbuster drugs, expanding its diagnostics business and adding steady revenue, which lifts the stock.

    Regulatory wins open new markets and deepen partnerships, directly boosting future sales.

  • Raised FY2026 guidance on China rebound and pharma growth Agilent raised full-year EPS guidance to $6.18–$6.21 after Q3 revenue rose 7.3% and China grew 9%. Strong pharma and advanced therapeutics demand, plus a $1 billion reshoring opportunity, point to faster growth ahead.

    Guidance raise and China recovery are the biggest new fundamental drivers for the stock.

  • Competition and sector sensitivity remain risks Danaher's Leica is expanding in pathology, and the life sciences tools sector is sensitive to growth outlook cuts. These pressures could cap Agilent's gains if investors worry about market share or a broader slowdown.

    Provides a fair counterweight to the positive news, showing what could hold the stock back.

Latest
▲3▼1

Agilent lifts guidance as China rebounds and diagnostics expand

  • AI cell analysis software and strong Q3 outlook Agilent launched AI-powered cell analysis software and guided Q3 revenue to $1.83–1.85 billion, above consensus. This shows its products are in demand and management is confident, which supports a higher stock price.

    New product and guidance signal future growth, a key driver for the stock.

  • FDA and EU approvals for cancer companion diagnostics Agilent won FDA and EU approvals for its PD-L1 tests in esophageal, gastric, and ovarian cancers. These tie its tests to blockbuster drugs, expanding its diagnostics business and adding steady revenue, which lifts the stock.

    Regulatory wins open new markets and deepen partnerships, directly boosting future sales.

  • Raised FY2026 guidance on China rebound and pharma growth Agilent raised full-year EPS guidance to $6.18–$6.21 after Q3 revenue rose 7.3% and China grew 9%. Strong pharma and advanced therapeutics demand, plus a $1 billion reshoring opportunity, point to faster growth ahead.

    Guidance raise and China recovery are the biggest new fundamental drivers for the stock.

  • Competition and sector sensitivity remain risks Danaher's Leica is expanding in pathology, and the life sciences tools sector is sensitive to growth outlook cuts. These pressures could cap Agilent's gains if investors worry about market share or a broader slowdown.

    Provides a fair counterweight to the positive news, showing what could hold the stock back.

Q2 2026
▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

June 2026
▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

© 2026 MarketIVWhy